Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
The first of four planned modules at the new plant is expected to come online by summer 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Subscribe To Our Newsletter & Stay Updated